SeaStar Medical Holding Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 12, 2026, reporting financial results for the three and nine months ended on that date.

Key Highlights

  • Net loss of $11.78 million for the nine months ended September 30, 2026, compared to a net loss of $9.246 million for the same period in 2025, according to the filing.
  • Net revenue of $1.745 million for the nine months ended September 30, 2026, up from $814 thousand in the comparable 2025 period.
  • Cash declined to $3.989 million at September 30, 2026, from $11.980 million at December 31, 2025.
  • Total stockholders' equity of $469 thousand at September 30, 2026, down from $10.416 million at December 31, 2025.
  • Accumulated deficit reached $163.494 million as of September 30, 2026, versus $151.714 million at December 31, 2025.
  • 5,315,967 shares of common stock outstanding as of November 1, 2026, per the filing.

SeaStar Medical's Financial Position and Operating Results for the Nine Months Ended September 30, 2026

SeaStar Medical Holding Corporation (NASDAQ:ICU), headquartered in Denver, Colorado, reported a net loss of $4.529 million for the three months ended September 30, 2026, compared to a net loss of $3.472 million in the same quarter of 2025, according to the filing. For the nine-month period, the net loss totaled $11.780 million, up from $9.246 million in the prior-year period. Net loss per share on a basic and diluted basis was $(1.03) for Q3 2026 and $(2.85) for the nine months ended September 30, 2026.

The company reported net revenue of $635 thousand for the three months ended September 30, 2026, compared to $183 thousand in Q3 2025. For the nine-month period, net revenue was $1.745 million, versus $814 thousand in the nine months ended September 30, 2025. Gross profit for the nine months was $1.597 million. Total operating expenses for the same period reached $13.572 million, driven by research and development expenses of $8.438 million and general and administrative expenses of $5.134 million, as disclosed in the filing.

On the balance sheet, total assets stood at $5.310 million as of September 30, 2026, down from $14.158 million at December 31, 2025, with cash falling to $3.989 million from $11.980 million. Total current liabilities rose to $4.841 million from $3.742 million. Common shares issued and outstanding were 4,461,965 at September 30, 2026, compared to 3,844,613 at December 31, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, as indicated on the filing's cover page.

What Was Disclosed

SeaStar Medical filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $11.780 million, revenue growth relative to the prior year, a sharp decline in cash, and reduced total stockholders' equity of $469 thousand.